Followers | 21 |
Posts | 355 |
Boards Moderated | 0 |
Alias Born | 02/26/2012 |
Friday, September 16, 2022 10:43:44 AM
Recent SHPH News
- Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma • GlobeNewswire Inc. • 09/16/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 09:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 09:23:05 PM
- Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease • GlobeNewswire Inc. • 09/05/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 08:26:42 PM
- Shuttle Pharma Provides Second Quarter 2024 Corporate Update • GlobeNewswire Inc. • 09/04/2024 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/04/2024 01:54:28 AM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 09/04/2024 01:52:57 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 09/04/2024 01:51:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 01:00:44 PM
- Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/28/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:10:24 PM
- Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) • GlobeNewswire Inc. • 08/26/2024 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:15:21 PM
- Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma • GlobeNewswire Inc. • 08/14/2024 08:10:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/13/2024 10:08:58 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 12:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 01:45:58 PM
- Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE • GlobeNewswire Inc. • 07/19/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:59:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 01:00:15 PM
- Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer • GlobeNewswire Inc. • 06/18/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/10/2024 10:12:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:15:20 PM
- Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • GlobeNewswire Inc. • 05/22/2024 08:15:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM